Streetbeat News

Regulatory

AMZN

The UK's antitrust regulator is set to investigate Amazon's AI partnership with Anthropic. This probe could have significant implications for Amazon's business operations and its competitive positioning in the AI market.

Portfolio Pulse from charles@benzinga.com

August 08, 2024 | 11:16 am

ALDX

Aldeyra Therapeutics announced that its Phase 3 trial for Reproxalap Ophthalmic Solution in treating dry eye disease achieved its primary endpoint, showing statistically superior results for ocular discomfort. The company plans to resubmit its NDA in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:15 am

APLS

Trading for APLS was halted at 6:55:00 a.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:55 am

ALDX

Trading in ALDX was halted at 6:55:00 a.m. ET pending news. Investors should stay tuned for updates as the halt indicates significant news is forthcoming.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:55 am

MRK

Merck has announced the discontinuation of its Phase 3 KeyVibe-008 trial based on the recommendation of an independent data monitoring committee. The trial did not meet the primary endpoint of overall survival and showed higher rates of adverse events in the treatment arm.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:47 am

BIVI

BioVie shares are trading higher after the company achieved alignment with the FDA on its upcoming SUNRISE-PD trial in Parkinson's disease. The company is conducting trial start-up activities with plans to initiate patient screening in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:15 am

FWONA

SPY

Liberty Media has received notification from the Department of Justice's Antitrust Division that an investigation has been opened regarding Formula 1's conduct concerning Andretti Formula Racing's application to enter the FIA Formula One World Championship.

Portfolio Pulse from charles@benzinga.com

August 08, 2024 | 10:13 am

BIVI

BioVie has aligned with the FDA on its upcoming SUNRISE-PD trial for Parkinson's disease, focusing on the effects of bezisterim (NE3107) on motor and non-motor symptoms in approximately 60 patients. The company plans to start patient screening in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:09 am

CRUZ

CRWD

DAL

JETS

MSFT

Delta Air Lines (DAL) is facing a class action lawsuit from passengers over inadequate refunds following a major computer outage. The lawsuit claims Delta breached contracts by not providing full refunds and only offering partial refunds in exchange for waivers against further legal claims. The outage, caused by a faulty software update from CrowdStrike (CRWD), led to a $500 million financial hit for Delta, which is now seeking damages from Microsoft (MSFT) and CrowdStrike. DAL stock has lost around 19% in the last 12 months.

Portfolio Pulse from Lekha Gupta

August 08, 2024 | 9:59 am

SPY

Economist Claudia Sahm has contradicted her own recession indicator, the Sahm Rule, stating that the U.S. is not currently in a recession but faces elevated risks. She advocates for potential interest rate cuts by the Federal Reserve. The recent weak jobs report has caused market turmoil, notably affecting the SPDR S&P 500 ETF Trust (NYSE:SPY).

Portfolio Pulse from Kaustubh Bagalkote

August 08, 2024 | 9:54 am